I. Jacobs

发表

Differential regulation of nicotinic receptor-mediated neurotransmitter release following chronic (-)-nicotine administration

C. Surowy, P. Puttfarcken, David J. Anderson, 2002, Neuropharmacology.

Long-term Safety and Efficacy of Subcutaneous C1-Inhibitor in Older Patients With Hereditary Angioedema.

William H. Yang, J. Bernstein, H. Farkas, 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Assessment of nicotinic acetylcholine receptor-mediated release of [3H]-norepinephrine from rat brain slices using a new 96-well format assay

C. Faltynek, P. Puttfarcken, David J. Anderson, 2000, Neuropharmacology.

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

M. Morfini, E. Santagostino, C. Négrier, 2012, Blood.

Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

E. Santagostino, T. Lissitchkov, A. Lubetsky, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Population pharmacokinetics of a new long‐acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B

M. Morfini, E. Santagostino, D. Bensen-Kennedy, 2016, Journal of thrombosis and haemostasis : JTH.

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

E. Santagostino, L. Boggio, C. Négrier, 2016, Blood.

Efficacy and safety of long‐acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

E. Santagostino, A. Lienhart, C. Négrier, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children

T. Lambert, E. Santagostino, H. Chambost, 2016, Thrombosis and Haemostasis.

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

E. Santagostino, A. Feussner, T. Limsakun, 2014 .

Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B

E. Santagostino, T. Lissitchkov, A. Lubetsky, 2013 .

Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.

K. Kawahata, J. Lawo, M. Hide, 2023, Allergology international : official journal of the Japanese Society of Allergology.

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

William H. Yang, P. Keith, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

Pharmacokinetic Profile of Subcutaneous C1-Esterase Inhibitor (C1-INH [SC]) in Adolescent and Adult Patients with Hereditary Angioedema (HAE)

I. Pragst, Dipti K. Pawaskar, I. Jacobs, 2018, Pediatrics.

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

William H. Yang, J. Bernstein, W. Lumry, 2023, The Lancet.

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

William H. Yang, P. Keith, W. Lumry, 2022, The Lancet.

Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings.

T. Machnig, J. Bernstein, W. Lumry, 2019, The journal of allergy and clinical immunology. In practice.

LONG-TERM EFFICACY AND SAFETY OF SUBCUTANEOUS C1-INHIBITOR IN ELDERLY PATIENTS WITH HEREDITARY ANGIOEDEMA TYPE I/II

J. Bernstein, I. Pragst, J. Chiao, 2018, Annals of Allergy, Asthma & Immunology.

Characterization of nicotinic acetylcholine receptor-mediated [3H]-dopamine release from rat cortex and striatum

C. Faltynek, P. Puttfarcken, I. Jacobs, 2000, Neuropharmacology.

Efficacy, PK and Safety Results of a Phase I/II Clinical Trial of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Haemophilia B (PROLONG - 9FP)

E. Santagostino, T. Lissitchkov, A. Lubetsky, 2012 .